 | • レポートコード：MRC2-11QY04962 • 出版社/出版日：QYResearch / 2020年11月20日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、91ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：ヘルスケア |
| Single User | ￥585,000 (USD3,900) | ▷ お問い合わせ |
| Multi User | ￥877,500 (USD5,850) | ▷ お問い合わせ |
| Enterprise License | ￥1,170,000 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料は子宮筋腫治療薬のグローバル市場について調査・分析したレポートです。種類別（経口、注射、その他）市場規模、用途別（病院、診療所、在宅医療、その他）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等）市場規模データ、主な企業情報と企業別市場シェア等が収録されています。 ・調査範囲 ・エグゼクティブサマリー ・企業別子宮筋腫治療薬の競争状況、市場シェア ・世界の子宮筋腫治療薬市場：種類別市場規模 2015年-2020年（経口、注射、その他） ・世界の子宮筋腫治療薬市場：種類別市場規模予測 2021年-2026年（経口、注射、その他） ・世界の子宮筋腫治療薬市場：用途別市場規模 2015年-2020年（病院、診療所、在宅医療、その他） ・世界の子宮筋腫治療薬市場：用途別市場規模予測 2021年-2026年（病院、診療所、在宅医療、その他） ・北米の子宮筋腫治療薬市場分析：米国、カナダ ・ヨーロッパの子宮筋腫治療薬市場分析：ドイツ、フランス、イギリス、イタリア、ロシア等 ・アジアの子宮筋腫治療薬市場分析：日本、中国、韓国、インド、オーストラリア、台湾等 ・中南米の子宮筋腫治療薬市場分析：メキシコ、ブラジル、アルゼンチン等 ・中東・アフリカの子宮筋腫治療薬市場分析：トルコ、サウジアラビア、UAE等 ・企業情報（企業概要、製品概要、販売量、企業動向） - 掲載企業（変更可能性あり）：GSK、Roche、Pfizer、Novartis、Merck、Bristol-Myers、Sanofi、Teva Pharmaceutical Industries、Amgen、Sun Pharmaceutical Industries、Bayer、Endo Pharmaceuticals、Allergan ・地域別市場規模予測（2021年-2026年）：北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場 ・市場機会、課題、リスク、環境分析 ・バリューチェーン、販売チャネル分析 ・調査の結論 |
Uterine fibroids are the most common benign tumors in female reproductive organs and one of the most common tumors in human body. They are mainly caused by proliferation of uterine smooth muscle cells.
Market Analysis and Insights: Global Uterine Fibroids Drug Market
The global Uterine Fibroids Drug market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX% during 2021-2026.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Uterine Fibroids Drug market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Uterine Fibroids Drug market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Uterine Fibroids Drug market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Uterine Fibroids Drug market.
Global Uterine Fibroids Drug Scope and Market Size
Uterine Fibroids Drug market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Uterine Fibroids Drug market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.
Market segment by Type, the product can be split into
Oral
Injection
Other
Market segment by Application, split into
Hospital
Clinic
Homecare
Other
Based on regional and country-level analysis, the Uterine Fibroids Drug market has been segmented as follows:
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia-Pacific
Latin America
Mexico
Brazil
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of Middle East & Africa
In the competitive analysis section of the report, leading as well as prominent players of the global Uterine Fibroids Drug market are broadly studied on the basis of key factors. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on price and revenue (global level) by player for the period 2015-2020.
The key players covered in this study
GSK
Roche
Pfizer
Novartis
Merck
Bristol-Myers
Sanofi
Teva Pharmaceutical Industries
Amgen
Sun Pharmaceutical Industries
Bayer
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Uterine Fibroids Drug Market Size Growth Rate by Type: 2020 VS 2026
1.2.2 Oral
1.2.3 Injection
1.2.4 Other
1.3 Market by Application
1.3.1 Global Uterine Fibroids Drug Market Share by Application: 2020 VS 2026
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Homecare
1.3.5 Other
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Uterine Fibroids Drug Market Perspective (2015-2026)
2.2 Global Uterine Fibroids Drug Growth Trends by Regions
2.2.1 Uterine Fibroids Drug Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Uterine Fibroids Drug Historic Market Share by Regions (2015-2020)
2.2.3 Uterine Fibroids Drug Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Uterine Fibroids Drug Players by Market Size
3.1.1 Global Top Uterine Fibroids Drug Players by Revenue (2015-2020)
3.1.2 Global Uterine Fibroids Drug Revenue Market Share by Players (2015-2020)
3.2 Global Uterine Fibroids Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Uterine Fibroids Drug Revenue
3.4 Global Uterine Fibroids Drug Market Concentration Ratio
3.4.1 Global Uterine Fibroids Drug Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Uterine Fibroids Drug Revenue in 2019
3.5 Key Players Uterine Fibroids Drug Area Served
3.6 Key Players Uterine Fibroids Drug Product Solution and Service
3.7 Date of Enter into Uterine Fibroids Drug Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Uterine Fibroids Drug Breakdown Data by Type (2015-2026)
4.1 Global Uterine Fibroids Drug Historic Market Size by Type (2015-2020)
4.2 Global Uterine Fibroids Drug Forecasted Market Size by Type (2021-2026)
5 Uterine Fibroids Drug Breakdown Data by Application (2015-2026)
5.1 Global Uterine Fibroids Drug Historic Market Size by Application (2015-2020)
5.2 Global Uterine Fibroids Drug Forecasted Market Size by Application (2021-2026)
6 North America
6.1 North America Uterine Fibroids Drug Market Size (2015-2026)
6.2 North America Uterine Fibroids Drug Market Size by Type (2015-2020)
6.3 North America Uterine Fibroids Drug Market Size by Application (2015-2020)
6.4 North America Uterine Fibroids Drug Market Size by Country (2015-2020)
6.4.1 United States
6.4.2 Canada
7 Europe
7.1 Europe Uterine Fibroids Drug Market Size (2015-2026)
7.2 Europe Uterine Fibroids Drug Market Size by Type (2015-2020)
7.3 Europe Uterine Fibroids Drug Market Size by Application (2015-2020)
7.4 Europe Uterine Fibroids Drug Market Size by Country (2015-2020)
7.4.1 Germany
7.4.2 France
7.4.3 U.K.
7.4.4 Italy
7.4.5 Russia
7.4.6 Nordic
7.4.7 Rest of Europe
8 China
8.1 China Uterine Fibroids Drug Market Size (2015-2026)
8.2 China Uterine Fibroids Drug Market Size by Type (2015-2020)
8.3 China Uterine Fibroids Drug Market Size by Application (2015-2020)
8.4 China Uterine Fibroids Drug Market Size by Region (2015-2020)
8.4.1 China
8.4.2 Japan
8.4.3 South Korea
8.4.4 Southeast Asia
8.4.5 India
8.4.6 Australia
8.4.7 Rest of Asia-Pacific
9 Japan
9.1 Japan Uterine Fibroids Drug Market Size (2015-2026)
9.2 Japan Uterine Fibroids Drug Market Size by Type (2015-2020)
9.3 Japan Uterine Fibroids Drug Market Size by Application (2015-2020)
9.4 Japan Uterine Fibroids Drug Market Size by Country (2015-2020)
9.4.1 Mexico
9.4.2 Brazil
10 Southeast Asia
10.1 Southeast Asia Uterine Fibroids Drug Market Size (2015-2026)
10.2 Southeast Asia Uterine Fibroids Drug Market Size by Type (2015-2020)
10.3 Southeast Asia Uterine Fibroids Drug Market Size by Application (2015-2020)
10.4 Southeast Asia Uterine Fibroids Drug Market Size by Country (2015-2020)
10.4.1 Turkey
10.4.2 Saudi Arabia
10.4.3 UAE
10.4.4 Rest of Middle East & Africa
11Key Players Profiles
11.1 GSK
11.1.1 GSK Company Details
11.1.2 GSK Business Overview
11.1.3 GSK Uterine Fibroids Drug Introduction
11.1.4 GSK Revenue in Uterine Fibroids Drug Business (2015-2020))
11.1.5 GSK Recent Development
11.2 Roche
11.2.1 Roche Company Details
11.2.2 Roche Business Overview
11.2.3 Roche Uterine Fibroids Drug Introduction
11.2.4 Roche Revenue in Uterine Fibroids Drug Business (2015-2020)
11.2.5 Roche Recent Development
11.3 Pfizer
11.3.1 Pfizer Company Details
11.3.2 Pfizer Business Overview
11.3.3 Pfizer Uterine Fibroids Drug Introduction
11.3.4 Pfizer Revenue in Uterine Fibroids Drug Business (2015-2020)
11.3.5 Pfizer Recent Development
11.4 Novartis
11.4.1 Novartis Company Details
11.4.2 Novartis Business Overview
11.4.3 Novartis Uterine Fibroids Drug Introduction
11.4.4 Novartis Revenue in Uterine Fibroids Drug Business (2015-2020)
11.4.5 Novartis Recent Development
11.5 Merck
11.5.1 Merck Company Details
11.5.2 Merck Business Overview
11.5.3 Merck Uterine Fibroids Drug Introduction
11.5.4 Merck Revenue in Uterine Fibroids Drug Business (2015-2020)
11.5.5 Merck Recent Development
11.6 Bristol-Myers
11.6.1 Bristol-Myers Company Details
11.6.2 Bristol-Myers Business Overview
11.6.3 Bristol-Myers Uterine Fibroids Drug Introduction
11.6.4 Bristol-Myers Revenue in Uterine Fibroids Drug Business (2015-2020)
11.6.5 Bristol-Myers Recent Development
11.7 Sanofi
11.7.1 Sanofi Company Details
11.7.2 Sanofi Business Overview
11.7.3 Sanofi Uterine Fibroids Drug Introduction
11.7.4 Sanofi Revenue in Uterine Fibroids Drug Business (2015-2020)
11.7.5 Sanofi Recent Development
11.8 Teva Pharmaceutical Industries
11.8.1 Teva Pharmaceutical Industries Company Details
11.8.2 Teva Pharmaceutical Industries Business Overview
11.8.3 Teva Pharmaceutical Industries Uterine Fibroids Drug Introduction
11.8.4 Teva Pharmaceutical Industries Revenue in Uterine Fibroids Drug Business (2015-2020)
11.8.5 Teva Pharmaceutical Industries Recent Development
11.9 Amgen
11.9.1 Amgen Company Details
11.9.2 Amgen Business Overview
11.9.3 Amgen Uterine Fibroids Drug Introduction
11.9.4 Amgen Revenue in Uterine Fibroids Drug Business (2015-2020)
11.9.5 Amgen Recent Development
11.10 Sun Pharmaceutical Industries
11.10.1 Sun Pharmaceutical Industries Company Details
11.10.2 Sun Pharmaceutical Industries Business Overview
11.10.3 Sun Pharmaceutical Industries Uterine Fibroids Drug Introduction
11.10.4 Sun Pharmaceutical Industries Revenue in Uterine Fibroids Drug Business (2015-2020)
11.10.5 Sun Pharmaceutical Industries Recent Development
11.11 Bayer
10.11.1 Bayer Company Details
10.11.2 Bayer Business Overview
10.11.3 Bayer Uterine Fibroids Drug Introduction
10.11.4 Bayer Revenue in Uterine Fibroids Drug Business (2015-2020)
10.11.5 Bayer Recent Development
11.12 Endo Pharmaceuticals
10.12.1 Endo Pharmaceuticals Company Details
10.12.2 Endo Pharmaceuticals Business Overview
10.12.3 Endo Pharmaceuticals Uterine Fibroids Drug Introduction
10.12.4 Endo Pharmaceuticals Revenue in Uterine Fibroids Drug Business (2015-2020)
10.12.5 Endo Pharmaceuticals Recent Development
11.13 Allergan
10.13.1 Allergan Company Details
10.13.2 Allergan Business Overview
10.13.3 Allergan Uterine Fibroids Drug Introduction
10.13.4 Allergan Revenue in Uterine Fibroids Drug Business (2015-2020)
10.13.5 Allergan Recent Development
12Analyst’s Viewpoints/Conclusions
13Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Table 1. Global Uterine Fibroids Drug Market Size Growth Rate by Type (US$ Million): 2020 VS 2026
Table 3. Key Players of Oral
Table 4. Key Players of Injection
Table 5. Key Players of Other
Table 6. Global Uterine Fibroids Drug Market Size Growth by Application (US$ Million): 2020 VS 2026
Table 7. Global Uterine Fibroids Drug Market Size by Regions (US$ Million): 2020 VS 2026
Table 8. Global Uterine Fibroids Drug Market Size by Regions (2015-2020) (US$ Million)
Table 9. Global Uterine Fibroids Drug Market Share by Regions (2015-2020)
Table 10. Global Uterine Fibroids Drug Forecasted Market Size by Regions (2021-2026) (US$ Million)
Table 11. Global Uterine Fibroids Drug Market Share by Regions (2021-2026)
Table 12. Uterine Fibroids Drug Market Market Trends
Table 13. Uterine Fibroids Drug Market Drivers
Table 14. Uterine Fibroids Drug Market Challenges
Table 15. Uterine Fibroids Drug Market Restraints
Table 16. Global Uterine Fibroids Drug Revenue by Players (2015-2020) (US$ Million)
Table 17. Global Uterine Fibroids Drug Market Share by Players (2015-2020)
Table 18. Global Top Uterine Fibroids Drug Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Uterine Fibroids Drug as of 2019)
Table 19. Global Uterine Fibroids Drug by Players Market Concentration Ratio (CR5 and HHI)
Table 20. Key Players Headquarters and Area Served
Table 21. Key Players Uterine Fibroids Drug Product Solution and Service
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. Global Uterine Fibroids Drug Market Size by Type (2015-2020) (US$ Million)
Table 24. Global Uterine Fibroids Drug Market Size Share by Type (2015-2020)
Table 25. Global Uterine Fibroids Drug Revenue Market Share by Type (2021-2026)
Table 26. Global Uterine Fibroids Drug Market Size Share by Application (2015-2020)
Table 27. Global Uterine Fibroids Drug Market Size by Application (2015-2020) (US$ Million)
Table 28. Global Uterine Fibroids Drug Market Size Share by Application (2021-2026)
Table 29. North America Uterine Fibroids Drug Market Size by Type (2015-2020) (US$ Million)
Table 30. North America Uterine Fibroids Drug Market Share by Type (2015-2020)
Table 31. North America Uterine Fibroids Drug Market Size by Application (2015-2020) (US$ Million)
Table 32. North America Uterine Fibroids Drug Market Share by Application (2015-2020)
Table 33. North America Uterine Fibroids Drug Market Size by Country (US$ Million) (2015-2020)
Table 34. North America Uterine Fibroids Drug Market Share by Country (2015-2020)
Table 35. Europe Uterine Fibroids Drug Market Size by Type (2015-2020) (US$ Million)
Table 36. Europe Uterine Fibroids Drug Market Share by Type (2015-2020)
Table 37. Europe Uterine Fibroids Drug Market Size by Application (2015-2020) (US$ Million)
Table 38. Europe Uterine Fibroids Drug Market Share by Application (2015-2020)
Table 39. Europe Uterine Fibroids Drug Market Size by Country (US$ Million) (2015-2020)
Table 40. Europe Uterine Fibroids Drug Market Share by Country (2015-2020)
Table 41. China Uterine Fibroids Drug Market Size by Type (2015-2020) (US$ Million)
Table 42. China Uterine Fibroids Drug Market Share by Type (2015-2020)
Table 43. China Uterine Fibroids Drug Market Size by Application (2015-2020) (US$ Million)
Table 44. China Uterine Fibroids Drug Market Share by Application (2015-2020)
Table 45. China Uterine Fibroids Drug Market Size by Region (US$ Million) (2015-2020)
Table 46. China Uterine Fibroids Drug Market Share by Region (2015-2020)
Table 47. Japan Uterine Fibroids Drug Market Size by Type (2015-2020) (US$ Million)
Table 48. Japan Uterine Fibroids Drug Market Share by Type (2015-2020)
Table 49. Japan Uterine Fibroids Drug Market Size by Application (2015-2020) (US$ Million)
Table 50. Japan Uterine Fibroids Drug Market Share by Application (2015-2020)
Table 51. Japan Uterine Fibroids Drug Market Size by Country (US$ Million) (2015-2020)
Table 52. Japan Uterine Fibroids Drug Market Share by Country (2015-2020)
Table 53. Southeast Asia Uterine Fibroids Drug Market Size by Type (2015-2020) (US$ Million)
Table 54. Southeast Asia Uterine Fibroids Drug Market Share by Type (2015-2020)
Table 55. Southeast Asia Uterine Fibroids Drug Market Size by Application (2015-2020) (US$ Million)
Table 56. Southeast Asia Uterine Fibroids Drug Market Share by Application (2015-2020)
Table 57. Southeast Asia Uterine Fibroids Drug Market Size by Country (US$ Million) (2015-2020)
Table 58. Southeast Asia Uterine Fibroids Drug Market Share by Country (2015-2020)
Table 59. GSK Company Details
Table 60. GSK Business Overview
Table 61. GSK Product
Table 62. GSK Revenue in Uterine Fibroids Drug Business (2015-2020) (US$ Million)
Table 63. GSK Recent Development
Table 64. Roche Company Details
Table 65. Roche Business Overview
Table 66. Roche Product
Table 67. Roche Revenue in Uterine Fibroids Drug Business (2015-2020) (US$ Million)
Table 68. Roche Recent Development
Table 69. Pfizer Company Details
Table 70. Pfizer Business Overview
Table 71. Pfizer Product
Table 72. Pfizer Revenue in Uterine Fibroids Drug Business (2015-2020) (US$ Million)
Table 73. Pfizer Recent Development
Table 74. Novartis Company Details
Table 75. Novartis Business Overview
Table 76. Novartis Product
Table 77. Novartis Revenue in Uterine Fibroids Drug Business (2015-2020) (US$ Million)
Table 78. Novartis Recent Development
Table 79. Merck Company Details
Table 80. Merck Business Overview
Table 81. Merck Product
Table 82. Merck Revenue in Uterine Fibroids Drug Business (2015-2020) (US$ Million)
Table 83. Merck Recent Development
Table 84. Bristol-Myers Company Details
Table 85. Bristol-Myers Business Overview
Table 86. Bristol-Myers Product
Table 87. Bristol-Myers Revenue in Uterine Fibroids Drug Business (2015-2020) (US$ Million)
Table 88. Bristol-Myers Recent Development
Table 89. Sanofi Company Details
Table 90. Sanofi Business Overview
Table 91. Sanofi Product
Table 92. Sanofi Revenue in Uterine Fibroids Drug Business (2015-2020) (US$ Million)
Table 93. Sanofi Recent Development
Table 94. Teva Pharmaceutical Industries Business Overview
Table 95. Teva Pharmaceutical Industries Product
Table 96. Teva Pharmaceutical Industries Company Details
Table 97. Teva Pharmaceutical Industries Revenue in Uterine Fibroids Drug Business (2015-2020) (US$ Million)
Table 98. Teva Pharmaceutical Industries Recent Development
Table 99. Amgen Company Details
Table 100. Amgen Business Overview
Table 101. Amgen Product
Table 102. Amgen Revenue in Uterine Fibroids Drug Business (2015-2020) (US$ Million)
Table 103. Amgen Recent Development
Table 104. Sun Pharmaceutical Industries Company Details
Table 105. Sun Pharmaceutical Industries Business Overview
Table 106. Sun Pharmaceutical Industries Product
Table 107. Sun Pharmaceutical Industries Revenue in Uterine Fibroids Drug Business (2015-2020) (US$ Million)
Table 108. Sun Pharmaceutical Industries Recent Development
Table 109. Bayer Company Details
Table 110. Bayer Business Overview
Table 111. Bayer Product
Table 112. Bayer Revenue in Uterine Fibroids Drug Business (2015-2020) (US$ Million)
Table 113. Bayer Recent Development
Table 114. Endo Pharmaceuticals Company Details
Table 115. Endo Pharmaceuticals Business Overview
Table 116. Endo Pharmaceuticals Product
Table 117. Endo Pharmaceuticals Revenue in Uterine Fibroids Drug Business (2015-2020) (US$ Million)
Table 118. Endo Pharmaceuticals Recent Development
Table 119. Allergan Company Details
Table 120. Allergan Business Overview
Table 121. Allergan Product
Table 122. Allergan Revenue in Uterine Fibroids Drug Business (2015-2020) (US$ Million)
Table 123. Allergan Recent Development
Table 124. Research Programs/Design for This Report
Table 125. Key Data Information from Secondary Sources
Table 126. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Uterine Fibroids Drug Market Share by Type: 2020 VS 2026
Figure 2. Oral Features
Figure 3. Injection Features
Figure 4. Other Features
Figure 5. Global Uterine Fibroids Drug Market Share by Application: 2020 VS 2026
Figure 6. Hospital Case Studies
Figure 7. Clinic Case Studies
Figure 8. Homecare Case Studies
Figure 9. Other Case Studies
Figure 10. Uterine Fibroids Drug Report Years Considered
Figure 11. Global Uterine Fibroids Drug Market Size (US$ Million), YoY Growth 2015-2026
Figure 12. Global Uterine Fibroids Drug Market Share by Regions: 2020 VS 2026
Figure 13. Global Uterine Fibroids Drug Market Share by Regions (2021-2026)
Figure 14. Global Uterine Fibroids Drug Market Share by Players in 2019
Figure 15. Global Top Uterine Fibroids Drug Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Uterine Fibroids Drug as of 2019
Figure 16. The Top 10 and 5 Players Market Share by Uterine Fibroids Drug Revenue in 2019
Figure 17. North America Uterine Fibroids Drug Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 18. United States Uterine Fibroids Drug Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 19. Canada Uterine Fibroids Drug Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 20. Europe Uterine Fibroids Drug Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 21. Germany Uterine Fibroids Drug Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 22. France Uterine Fibroids Drug Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 23. U.K. Uterine Fibroids Drug Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 24. Italy Uterine Fibroids Drug Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 25. Russia Uterine Fibroids Drug Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 26. Nordic Uterine Fibroids Drug Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 27. Rest of Europe Uterine Fibroids Drug Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 28. Asia-Pacific Uterine Fibroids Drug Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 29. China Uterine Fibroids Drug Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 30. Japan Uterine Fibroids Drug Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 31. South Korea Uterine Fibroids Drug Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 32. Southeast Asia Uterine Fibroids Drug Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 33. India Uterine Fibroids Drug Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 34. Australia Uterine Fibroids Drug Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 35. Rest of Asia-Pacific Uterine Fibroids Drug Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 36. Latin America Uterine Fibroids Drug Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 37. Mexico Uterine Fibroids Drug Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 38. Brazil Uterine Fibroids Drug Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 39. Middle East & Africa Uterine Fibroids Drug Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 40. Turkey Uterine Fibroids Drug Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 41. Saudi Arabia Uterine Fibroids Drug Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 42. UAE Uterine Fibroids Drug Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 43. Rest of Middle East & Africa Uterine Fibroids Drug Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 44. GSK Revenue Growth Rate in Uterine Fibroids Drug Business (2015-2020)
Figure 45. Roche Revenue Growth Rate in Uterine Fibroids Drug Business (2015-2020)
Figure 46. Pfizer Revenue Growth Rate in Uterine Fibroids Drug Business (2015-2020)
Figure 47. Novartis Revenue Growth Rate in Uterine Fibroids Drug Business (2015-2020)
Figure 48. Merck Revenue Growth Rate in Uterine Fibroids Drug Business (2015-2020)
Figure 49. Bristol-Myers Revenue Growth Rate in Uterine Fibroids Drug Business (2015-2020)
Figure 50. Sanofi Revenue Growth Rate in Uterine Fibroids Drug Business (2015-2020)
Figure 51. Teva Pharmaceutical Industries Revenue Growth Rate in Uterine Fibroids Drug Business (2015-2020)
Figure 52. Amgen Revenue Growth Rate in Uterine Fibroids Drug Business (2015-2020)
Figure 53. Sun Pharmaceutical Industries Revenue Growth Rate in Uterine Fibroids Drug Business (2015-2020)
Figure 54. Bayer Revenue Growth Rate in Uterine Fibroids Drug Business (2015-2020)
Figure 55. Endo Pharmaceuticals Revenue Growth Rate in Uterine Fibroids Drug Business (2015-2020)
Figure 56. Allergan Revenue Growth Rate in Uterine Fibroids Drug Business (2015-2020)
Figure 57. Bottom-up and Top-down Approaches for This Report
Figure 58. Data Triangulation
Figure 59. Key Executives Interviewed
子宮筋腫の世界市場（～2026年） Uterine fibroids (myoma) are benign (non-cancerous) lumps that grow in the muscular wall of the uterus. They vary in sizes, from minute (a quarter of an inch) to the size of more than16 centimeters. The incidence of uterine fibroid is about 20%–40% in women during their reproductive ages. Occasional…- 子宮内膜ポリープ治療薬の世界市場（～2026年） Uterine polyps are common gynecological diseases. Broadly speaking, it refers to all tumors attached to the uterine wall by slender pedicle. Mostly benign. Market Analysis and Insights: Global Uterine Polyps Drug Market The global Uterine Polyps Drug market size is projected to reach US$ XX million …
- 子宮がん診断検査の世界市場（～2026年） Uterus a female organ also referred as the womb is located in the lower abdomen. It supports in the fetal development until birth. In North America, the U.S. is expected to be the dominant market for uterine cancer diagnostic testing due to growing incidence of uterine cancer. Market Analysis and In…
- 子宮疾患治療薬の世界市場（～2026年） Uterus is the muscle organ in female reproductive system, which plays a great role in female reproduction and fetal development. The incidence of uterine diseases is also very high, so the treatment of uterine diseases is particularly important. Market Analysis and Insights: Global Uterine Diseases …
- 子宮筋腫治療装置の世界市場（～2026年） Uterine fibroids are noncancerous growths of the uterus that often appear during childbearing years. Also called leiomyomas (lie-o-my-O-muhs) or myomas, uterine fibroids aren't associated with an increased risk of uterine cancer and almost never develop into cancer. Market Analysis and Insights: Glo…